Cold agglutinin-induced acrocyanosis in a patient with subclinical chronic lymphocytic leukemia; a beneficial response to rituximab.
Shirafuji
Yoshinori
Y
Maeda
Yoshinobu
Y
Iwatsuki
Keiji
K
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003450:Cryoglobulins / Q000009:adverse effects / Q000627:therapeutic use; D003490:Cyanosis / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy; D005385:Fingers; D005500:Follow-Up Studies; D006388:Hemagglutinins / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D003450:Cryoglobulins; D006388:Hemagglutinins; C029443:cold agglutinins; D000069283:Rituximab